Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) manifests as proximal and distal weakness, areflexia, and sensory impairments progressing for at least 2 months [1] . The diagnosis relies on the clinical presentation and nerve conduction studies (NCS) that show demyelinating neuropathy [2] . The treatment options for CIDP include intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin, plasma exchange, corticosteroids, and other immunosuppressive drugs such as azathioprine [3] [4] [5] . Electrophysiological studies are essential for the diagnosis of CIDP, but the utility of NCS in monitoring outcomes in individual CIDP patients is controversial. In large patient cohorts, NCS, an objective measure of disease burden, are associated with clinical deficits [6] [7] [8] [9] . Most previous controlled studies in CIDP have been short-term and the capacity for change in NCS may be restricted in such brief time intervals. Despite this consideration, several studies have shown electrophysiological improvement with treatment and correlations with clinical outcomes [6, 7, 9] . In addition, prediction of relapses with changes in NCS has been observed with a higher number of demyelinating changes heralding clinical relapse [8] . Here we present a patient treated for CIDP since 1988 and describe the electrophysiological changes with time in an effort to highlight the benefits and limitations of electrophysiology in CIDP management.
Case Presentation
A 25-year-old man presented in 1988 with a 6-month history of progressive numbness, tingling, generalized fatigue, and weakness in the upper and lower limbs. Examination showed grade 4 weakness of elbow, wrist, hand, hip flexor, hamstring, and quadriceps muscles and grade 3 power of more distal muscles in the legs. He had a coarse postural tremor, areflexia, and flexor plantar responses. Sensory testing showed a glove-and-stocking hypesthesia to pinprick and temperature extending to the mid-forearms and knees. Joint position was impaired at the toes and fingertips, and vibration sense was impaired distally in the toes. He had mild bilateral foot-drop gait and walked on a broadened base. He could not perform a tandem gait and the Romberg test was positive. He could not walk on heels or toes.
NCS showed demyelinating polyneuropathy with secondary axonal loss ( Table 1) . Electromyographic examination showed fibrillation potentials, monophasic positive sharp waves, and reduced recruitment indicating axonal loss. The patient was diagnosed with CIDP and treated with prednisone and azathioprine. He improved clinically over the next 6 months with mild residual weakness, sensory loss, and areflexia, but NCS were unchanged. By 1990, he had more clinical improvement, with improved NCS as shown in Table 1 with increased compound muscle action potential amplitudes and motor nerve conduction velocities as well as decreased distal motor and F wave latencies.
By mid-1992, he was asymptomatic with a normal examination apart from persistent areflexia. By 1993, he was able to play hockey, and prednisone was stopped. As azathioprine was slowly tapered to 25 mg daily by 1995, he remained well clinically, but F wave latencies increased (Table 1 ). This increase in F wave latencies heralded a clinical relapse in 1996 that responded completely to a higher dose of azathioprine, but the NCS improved more slowly by 1998, although not fully, and he relapsed twice more as azathioprine was tapered.
By 2005 he felt 95-100% of normal, ran 5 miles daily, and worked full time. His upper limb reflexes were normal and he had sluggish knee reflexes. Strength was intact and he had mild distal sensory loss of pinprick. Azathioprine was slowly tapered and stopped in 2011, and by 2012 his NCS were normal (Table 1) . He relapsed in 2016 following a respiratory tract infection and responded to IVIG and azathioprine after 10 months when the IVIG was discontinued, although the NCS were unchanged. By late 2018, the patient was 100% of normal with normal strength, hypoactive reflexes in the upper limbs and absent reflexes in the lower limbs, as well as normal sensation and gait. NCS were normal and azathioprine was discontinued in 2019.
Discussion
There is controversy about the role of NCS in monitoring outcomes of CIDP treatment on a study population and on the patient level [6] [7] [8] [9] . Our patient with CIDP was monitored for more than 30 years with serial clinical evaluations and electrophysiology, showing positive, major responses in both after treatment. Generally, the improvements in NCS lagged behind the clinical state for up to 2 years (i.e., 1996-1998), but clearly improved with treatment, and also deteriorated (in 1995) preceding a clinical relapse. This case illustrates that NCS can provide an objective measure of treatment success and also warn of impending clinical relapse. Electrophysiology might serve as a guide when making treatment decisions about tapering effective medications in an apparently clinically stable patient.
Conclusion
CIDP is a chronic condition that needs to be monitored closely. This case illustrates that electrophysiological assessments show delayed recovery after clinical improvement and can predict relapse on an individual patient basis. CMAP, compound muscle action potential; CV, conduction velocity; ML, motor latency; NR, not reported.
